Category: Kevin Outterson

We’re in Dire Need of New Funding for Antibiotics, Researchers Say

February 26th, 2015 in 2015, Kevin Outterson, Newsmakers, School of Law 0 comments

Kevin-Outterson-260x300Motherboard
Kevin Outterson, School of Law

As a global community, we’re in a high-stakes race against rapidly developing antibiotic resistance—and we’re losing…

Expert quote: 

“There are a dozen cancer therapies that are more than $100,000 for a course of treatment, despite very modest proof of efficacy. Meanwhile a course of new antibiotics costs something like $2-3,000 dollars.”

View full article

What a world without antibiotics could look like — and how to prevent it

February 17th, 2015 in 2015, Kevin Outterson, Newsmakers, School of Law 0 comments

Kevin-Outterson-260x300Vox
Kevin Outterson, School of Law

It’s not an overstatement to say that most of modern medicine and our health hinges on the effectiveness of antibiotics…

Expert quote:

“It’s almost unimaginable how going back to a pre-antibiotic era would affect US health care.”

View full article

Scientists maybe, possibly just discovered an amazing new antibiotic

January 9th, 2015 in 2015, Kevin Outterson, Newsmakers, School of Law 0 comments

Kevin-Outterson-260x300Vox
Kevin Outterson, School of Law

This week, according to major media outlets around the world, a “breakthrough” antibiotic was discovered. This new antibiotic — found in dirt, no less — “could prove resistant to resistance,” one excited headline read…

Expert quote:

“The data on the new drug is just in vitro and mouse models.”

View full article

Antibiotic Resistance Will Kill 300 Million People By 2050

December 16th, 2014 in 2014, Kevin Outterson, Newsmakers, School of Law, Scientific American 0 comments

Kevin-Outterson-260x300Scientific American
Kevin Outterson, School of Law

The true cost of antimicrobial resistance (AMR) will be 300 million premature deaths and up to $100 trillion (£64 trillion) lost to the global economy by 2050…

Expert quote:

“You can look at antibiotic resistance as a slow moving global train wreck, which will happen over the next 35 years. If we do nothing, this report shows us the likely magnitude of the costs.”

View full article

Drug-resistant infections could cost the global economy $100 trillion by 2050

December 13th, 2014 in 2014, Fortune, Kevin Outterson, Newsmakers, School of Law 0 comments

Kevin-Outterson-260x300Fortune
Kevin Outterson, School of Law

It’s time for better antibiotics, new report says…

Expert quote:

The research requires “much careful additional work, but it correctly identifies the magnitude of the problem and the potential macroeconomic impact. It should also help us frame an appropriate response.”

View full article

The Race for an Ebola Vaccine

November 25th, 2014 in 2014, Ebola, Kevin Outterson, Newsmakers, School of Law 0 comments

Kevin-Outterson-260x300The New Yorker
Kevin Outterson, School of Law

Over the summer, as it became clear that the Ebola outbreak in West Africa was one of the worst public-health emergencies in recent memory, executives at Merck met at the company’s New Jersey headquarters to figure out how to respond…

Expert quote:

“Every drug company cares about their reputation, and various companies have had various hits to their reputation over the past decade, so if they can do something that’s clearly helping with an urgent global public-health need at a reasonable cost, it’s a good move for everybody.”

View full article

Experts Media Alert: SCOTUS to hear challenge to Affordable Care Act

November 10th, 2014 in 2014, Abigail Moncrieff, Alan Cohen, Experts Media Alert, Kevin Outterson, News Releases, School of Law, School of Management, Stephen Davidson 0 comments

512px-Oblique_facade_2,_US_Supreme_CourtThe Supreme Court will review a unanimous federal appeals court ruling that upheld Internal Revenue Service regulations that allow health-insurance tax credits under the Affordable Care Act for consumers in all 50 states. Opponents argue that most of the subsidies are illegal. The following Boston University professor are available for comment and analysis:

Abigail Moncrieff is an associate professor of law and an authority on health-care law. She is quoted frequently on Obamacare and authored a piece on Boston.com in June 2012 titled “Why did the Supreme Court uphold the Affordable Care Act?”Moncrieff can be reached at 617-353-2212 or arm11@bu.edu.

Kevin Outterson is a professor of law and an authority on food and drug law, drug marketing, and director of the BU Health Law Program.  He also is editor-in-chief of The Journal of Law, Medicine & Ethics and blogs on health policy issues on The Incidental Economist. Outterson can be reached at 617-353-3103 or mko@bu.edu.

Profs. Moncrieff and Outterson led a team of BU Law students file four amicus briefs supporting the Affordable Care Act, which was heard by the Supreme Court in the spring. The work was cited by Supreme Court Justice Ruth Bader Ginsburg in her decision of Obamacare.

Stephen Davidson is a professor of healthcare management in BU’s School of Management and author of Still Broken: Understanding the U.S. Healthcare System. In October 2013, he wrote Opposition to Obamacare is maddening, a point-of-view piece for BU Today. He has also written several pieces on the Affordable Care Act for The Huffington Post. Davidson can be reached at 617-353-7422 or sdavidso@bu.edu.

Alan Cohen is a professor of health policy and management and the Program Director of the Robert Wood Foundation Scholars in Health Policy Research. Contact Cohen at 617-353-9222 or abcohen@bu.edu.

 

 

BARDA: The venture capital firm buried in the U.S. government

October 31st, 2014 in 2014, Kevin Outterson, Marketplace, Newsmakers, School of Law 0 comments

Kevin-Outterson-260x300Marketplace
Kevin Outterson, School of Law

For five years, John Eldridge and his team at Profectus Bioscience have developed and tested their Ebola vaccine. First it was on guinea pigs, then monkeys…

Expert quote:

“They are investing in things that would die if they didn’t have additional funding.”

View full article and listen to audio

Why Reducing Antibiotic Resistance Is Harder Than It Seems

September 19th, 2014 in 2014, Kevin Outterson, Newsmakers, School of Law, Time 0 comments

Kevin-Outterson-260x300Time
Kevin Outterson, School of Law

Just a day after President Obama announced an executive order to create a task force and action plan for confronting antibiotic resistance, the House Energy & Commerce Committee held a hearing on antibiotic resistance and how to foster new drug development…

Expert quote:

“Resistance genes have been found throughout the agricultural sector, including dairy cows that did not receive antibiotics. We should launch serious research efforts to find and deploy techniques to reduce the need for antibiotics in agriculture and to reduce health risks to humans, including animal husbandry, vaccines, alternative forms of growth promotion, and other innovations.”

View full article

Ebolanomics

August 21st, 2014 in 2014, Ebola, Kevin Outterson, Newsmakers, School of Law 0 comments

Kevin-Outterson-260x300The New Yorker
Kevin Outterson, School of Law

The deadly hemorrhagic fever Ebola was first discovered in 1976, and it has haunted the public imagination for twenty years, ever since the publication of Richard Preston’s “The Hot Zone.” Yet, in all that time, no drug has ever been approved to treat the disease…

Expert quote:

“Antibiotic resistance really has the potential to make everything about the way we live different. So we need to stoke the pipeline.”

View full article